Allendale, New Jersey – Kingchem Life Science has announced a multi-phase strategic growth initiative which is centered around Kingchem Laboratories, Kingchem’s cGMP manufacturing facility located in St. Francis, Wisconsin in the United States. Kingchem has entered into an agreement to purchase additional property in Wisconsin to expand the footprint of our manufacturing facility.
Kingchem’s neighboring property at 4200 S Nevada Ave, St. Francis, WI has been owned by PDQ Tooling for several decades, but PDQ has agreed to terms for the sale of the existing buildings and unimproved land bordering on the south side of Kingchem’s property.
“Kingchem will be well-positioned to continue to add both new technologies as well as increased manufacturing capacity from our cGMP facility in the US. Kingchem’s customers are sure to be excited by this news, especially following so closely after the recent FDA inspection which resulted in no 483s,” said Ryan Yoder, Senior Vice President of Business Development at Kingchem.
From a personnel standpoint, this expansion will allow for growth at every level of the organization. Kingchem will be adding senior leadership to oversee all aspects of the facility in addition to the strategic growth effort. Kingchem has also created a new department on site which will be dedicated to Analytical Development. This is in addition to the hiring of an experienced QA Manager at the end of 2024 and additional hiring planned later this year.
In the short term, Kingchem plans to quickly make use of the additional space for a state-of-the-art upgrade for the analytical team. Kingchem plans to expand the QC footprint to allow more space for instrumentation including a new ICP-MS planned for later this year. This expansion will also serve to create additional space for the new Analytical Development department’s dedicated instruments.
The above expansion will also create additional space inside the existing manufacturing facility for further growth. Looking ahead to later phases of Kingchem’s strategic growth plan, this new property will provide Kingchem with a large portion of undeveloped land to serve as a new home for future manufacturing expansions.
Kingchem’s Chief Executive Officer, Stephen Wang, commented on how exciting this news is for Kingchem and for Kingchem’s customers.
“Since acquiring Kingchem Laboratories in Wisconsin in 2018, Kingchem has consistently invested in this facility and this expansion further extends our commitment to our employees and to our customers,” Wang said.
Kingchem is a publicly traded, global CDMO with >51% controlling equity stake owned by US shareholders and US management team. Kingchem maintains a focus on the pharmaceutical industry offering cGMP manufacturing services in the United States and non-GMP manufacturing services in China. For more information on Kingchem, please visit our website at https://www.kingchem.com/.
Ready to partner with Kingchem?
Partner with Kingchem and leverage our global network, advanced capabilities, and commitment to quality to conquer your most challenging pharmaceutical and specialty chemical projects.